Alcon Inc. (ALC)
Automate Your Wheel Strategy on ALC
With Tiblio's Option Bot, you can configure your own wheel strategy including ALC - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ALC
- Rev/Share 20.2443
- Book/Share 44.689
- PB 1.7149
- Debt/Equity 0.2375
- CurrentRatio 2.6015
- ROIC 0.0424
- MktCap 37861152000.0
- FreeCF/Share 3.2276
- PFCF 23.688
- PE 35.3424
- Debt/Assets 0.1673
- DivYield 0.0044
- ROE 0.0493
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 3
- P/B Score 3
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | ALC | JP Morgan | Overweight | Neutral | -- | -- | Aug. 21, 2025 |
| Downgrade | ALC | Deutsche Bank | Buy | Hold | -- | -- | May 20, 2025 |
| Reiterated | ALC | BTIG Research | -- | Buy | $102 | $99 | May 14, 2025 |
| Reiterated | ALC | Needham | -- | Buy | $107 | $110 | March 28, 2025 |
| Upgrade | ALC | BofA Securities | Neutral | Buy | -- | -- | March 25, 2025 |
| Reiterated | ALC | Needham | -- | Buy | $108 | $106 | Jan. 24, 2025 |
| Upgrade | ALC | Redburn Atlantic | Neutral | Buy | -- | -- | Jan. 10, 2025 |
| Reiterated | ALC | Needham | -- | Buy | $103 | $108 | Dec. 17, 2024 |
| Upgrade | ALC | Redburn Atlantic | Sell | Neutral | -- | -- | Oct. 10, 2024 |
| Upgrade | ALC | RBC Capital Mkts | Sector Perform | Outperform | -- | -- | Sept. 10, 2024 |
News
ALC Stock May Rise With the Introduction of PanOptix Pro in US
Published: April 03, 2025 by: Zacks Investment Research
Sentiment: Neutral
Alcon introduces Clareon PanOptix Pro IOL to select practices across the United States, with commercial availability expected in May.
Read More
LENSAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of LENSAR, Inc. - LNSR
Published: March 26, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of LENSAR, Inc. (NasdaqCM: LNSR) to Alcon Inc. (NYSE: ALC). Under the terms of the proposed transaction, shareholders of LENSAR will receive $14.00 in cash, with an additional non-tradeable contingent value right offering up to $2.75 per share in cash conditioned on achievement of a milestone, for each.
Read More
Alcon Announces CE Mark Approval and Commercialization of Clareon Vivity IOL in Europe, Expanding Visual Possibilities
Published: March 25, 2025 by: Business Wire
Sentiment: Neutral
GENEVA--(BUSINESS WIRE)--Alcon Announces CE Mark Approval and Commercialization of Clareon Vivity IOL in Europe, Expanding Visual Possibilities.
Read More
Alcon Agrees to Acquire LENSAR, Inc.
Published: March 24, 2025 by: Business Wire
Sentiment: Neutral
GENEVA, Switzerland & ORLANDO, Fla.--(BUSINESS WIRE)--Alcon Agrees to Acquire LENSAR, Inc.
Read More
Retinal Surgery Devices Market Outlook Report 2025-2033: Revenues Set to Double, Reaching $4.83 Billion by 2033, Led by Topcon Corp., Alcon, and Carl Zeiss
Published: March 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
Dublin, March 24, 2025 (GLOBE NEWSWIRE) -- The "Retinal Surgery Devices Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033" has been added to ResearchAndMarkets.com's offering. The Retinal Surgery Devices Market is expected to reach US$ 4.84 billion in 2033 from US$ 2.48 billion in 2024, with a CAGR of 7.71% from 2025 to 2033. Some of the main reasons propelling the market include the rising prevalence of a number of eye ailments, increased awareness of eye issues and available treatments, and the expanding use of minimally invasive (MI) surgical technology. Rising prevalence of retinal diseases The …
Read More
Alcon to Host 2025 Capital Markets Day
Published: March 13, 2025 by: Business Wire
Sentiment: Neutral
GENEVA--(BUSINESS WIRE)--Alcon to Host 2025 Capital Markets Day.
Read More
Alcon to Host 2025 Capital Markets Day
Published: March 13, 2025 by: Business Wire
Sentiment: Neutral
GENEVA--(BUSINESS WIRE)--Alcon to Host 2025 Capital Markets Day.
Read More
Watch CNBC's full interview with Alcon CEO David Endicott
Published: February 26, 2025 by: CNBC International TV
Sentiment: Neutral
Alcon CEO David Endicott discusses the pharmaceutical firm's full-year results.
Read More
Alcon Inc. (ALC) Q4 2024 Earnings Call Transcript
Published: February 26, 2025 by: Seeking Alpha
Sentiment: Neutral
Alcon Inc. (NYSE:ALC ) Q4 2024 Earnings Conference Call February 26, 2025 8:00 AM ET Company Participants Dan Cravens - Vice President, Investor Relations David Endicott - Chief Executive Officer Tim Stonesifer - Chief Financial Officer Conference Call Participants David Saxon - Needham & Company Jeff Johnson - Baird Ryan Zimmerman - BTIG Larry Biegelsen - Wells Fargo Julien Ouaddour - Bank of America Patrick Wood - Morgan Stanley David Adlington - JPMorgan Brett Fishbin - Keybanc Capital Markets Harry Shrives - Citi Tom Stephan - Stifel Issie Kirby - Redburn Atlantic Kavya Deshpande - UBS Jack Reynolds-Clark - RBC …
Read More
Alcon Q4 Earnings Beat, Margins Rise, Stock Remains Stable in Afterhours
Published: February 26, 2025 by: Zacks Investment Research
Sentiment: Positive
ALC's performance is driven by robust demand for its innovative products, balanced geographic footprint and strong execution by the team.
Read More
Alcon eyes revenue growth in 2025 after in-line results
Published: February 26, 2025 by: Reuters
Sentiment: Positive
Alcon forecast sales of between $10.2 and $10.4 billion for 2025, after the eye care group reported higher fourth-quarter revenue underpinned by its surgical division on Tuesday.
Read More
Alcon (ALC) Reports Q4 Earnings: What Key Metrics Have to Say
Published: February 25, 2025 by: Zacks Investment Research
Sentiment: Neutral
While the top- and bottom-line numbers for Alcon (ALC) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Read More
About Alcon Inc. (ALC)
- IPO Date 2019-04-09
- Website https://www.alcon.com
- Industry Medical - Instruments & Supplies
- CEO David J. Endicott
- Employees 25599